Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials.
about
Identification of PDCL3 as a novel chaperone protein involved in the generation of functional VEGF receptor 2Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding siteIdentification of protein kinase D2 as a pivotal regulator of endothelial cell proliferation, migration, and angiogenesisRole of Neuropilin-1 in Diabetic NephropathyRole of c-Cbl-dependent regulation of phospholipase Cgamma1 activation in experimental choroidal neovascularizationStudies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis)Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbitsLysine methylation promotes VEGFR-2 activation and angiogenesis.Kaposi's sarcoma herpesvirus K15 protein contributes to virus-induced angiogenesis by recruiting PLCĪ³1 and activating NFAT1-dependent RCAN1 expression.Structural and functional characterization of two alternative splicing variants of mouse Endothelial Cell-Specific Chemotaxis Regulator (ECSCR)Angiogenic, hyperpermeability and vasodilator network in utero-placental units along pregnancy in the guinea-pig (Cavia porcellus).Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus diseaseVascular endothelial growth factor in eye disease.Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.Vascular endothelial growth factor acts through novel, pregnancy-enhanced receptor signalling pathways to stimulate endothelial nitric oxide synthase activity in uterine artery endothelial cells.Vascular endothelial growth factor (VEGF) receptor-2 tyrosine 1175 signaling controls VEGF-induced von Willebrand factor release from endothelial cells via phospholipase C-gamma 1- and protein kinase A-dependent pathwaysCandidate gene association study for diabetic retinopathy in Chinese patients with type 2 diabetes.Identification of a gene expression profile associated with the regulation of angiogenesis in endometrial cancer.Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.Vascular precursor cells in tissue injury repair.Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.The role of SRC family kinases in prostate cancer.Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies.Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity.Effect of DAPT, a gamma secretase inhibitor, on tumor angiogenesis in control mice.VEGF-A isoform-specific regulation of calcium ion flux, transcriptional activation and endothelial cell migration.Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor.Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP.HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses.MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth.Modulation of VEGF signaling in a mouse model of diabetes by xanthohumol and 8-prenylnaringenin: Unveiling the angiogenic paradox and metabolism interplay.Angiodysplasia in embryo lacking protein arginine methyltransferase 1 in vascular endothelial cells.The VEGFR2 receptor tyrosine kinase undergoes constitutive endosome-to-plasma membrane recycling.Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis, and Biological Evaluation.Generation of recombinant extracellular fragment of vascular endothelial growth factor receptor 2 and specific monoclonal antibodies to this receptor.Expression of the vascular endothelial growth factor (VEGF-A) and its receptors in the umbilical cord in the course of pregnancy in the pig.Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors.
P2860
Q24296686-5F022A1F-A5A6-4446-B13B-BC4CDDFC5220Q24302190-F8AB789D-21D3-4ADD-BB0E-F076D6B06327Q24313566-20523EE3-FEF9-4B18-AB41-47D481BDC56DQ26799448-22386E97-04D8-40EE-A45A-B4063BB0DFD4Q33622273-BAB1DFAB-B515-42A2-8297-C6ED1FB59BC6Q33787955-2238F28D-BC0D-45E7-B58D-A905D8FCF7CBQ33911625-808EAEA6-F992-4B12-BEF1-CF231FEA4697Q33940384-53401453-2C17-4483-AA87-E07B35B293C4Q34426472-5700EC5D-802A-482B-BB46-BB3B6B5A78FEQ35934057-2018277B-16D0-4770-A8A7-5987B6068E47Q36535272-BE9CB8B9-B9D9-422F-9D11-9CEE1C71EB47Q36761991-8BF95782-252A-4749-B7EB-74B4BDCC0F3AQ36929380-99FB575F-EA00-4CF4-B7E7-2FD99C09A651Q37173281-DFDA04B9-AC83-41F5-ADE1-5471E164FF10Q37188408-D8DBF75C-5D9E-4FD8-986F-E2464064D771Q37358053-F0E166CA-E20F-4941-85EB-27C6182FCA6EQ37623447-BD828493-7D17-4CA0-979E-AE2BC87E8A28Q38665853-E6506EFB-9CE4-4EF1-A6BC-06FE5D95DAD4Q39146512-2FFD2384-E4F1-452F-920F-F78B9FAECD1DQ39174289-889A2F3D-A345-433D-AE82-B90F664EE6C4Q39728936-9176D1B1-7669-4AD9-AB04-8D972D2899E6Q40055337-1FD0832A-E4DE-4249-9BE7-FA6BAFF0513CQ41494887-CFAA7F05-84E9-4D1C-A0D9-711E97BD54F5Q41829449-86BF8881-419F-42CD-8F7A-83DA57735A21Q41903209-DC485FC5-6A88-487D-9539-9AE4AC6FCA95Q41961850-8E696514-72B9-4BA4-9E59-710A5917F833Q42431654-D798DABF-850C-416C-B7D0-BE9CF70269A7Q42577163-26B1D1B8-EBEC-45AC-B9B2-2E2F8D91D1E7Q43096150-41EF1EA1-462D-4AF4-A3FC-37C746B2F4A0Q50062976-86A62894-68AD-4791-882F-29246D6BC2E6Q51026280-5BFB781B-CEDD-40B5-A9B0-2BE1590A1DB7Q51243727-490AAEE2-6E11-4DF5-85EE-2DBB8735FC9BQ52845770-E0D4D863-4F56-4C0D-887F-3BF825CECC47Q54228215-D6C77E53-6D60-4CC7-B81E-1E2D61BAD414Q54356838-5FCF9034-471B-4471-AB9D-C6C46857B55DQ54412258-39515C9C-B517-48C6-852C-1302B5D03F30Q54477930-01715EEA-5E94-4C63-82C8-8EE9FEFB083C
P2860
Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials.
description
2006 nĆ® lÅ«n-bĆ»n
@nan
2006 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ”ÕµÕ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2006 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ“Õ”ÕµÕ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2006幓ć®č«ę
@ja
2006幓č«ę
@yue
2006幓č«ę
@zh-hant
2006幓č«ę
@zh-hk
2006幓č«ę
@zh-mo
2006幓č«ę
@zh-tw
2006幓č®ŗę
@wuu
name
Vascular endothelial growth fa ...... on and therapeutic potentials.
@ast
Vascular endothelial growth fa ...... on and therapeutic potentials.
@en
type
label
Vascular endothelial growth fa ...... on and therapeutic potentials.
@ast
Vascular endothelial growth fa ...... on and therapeutic potentials.
@en
prefLabel
Vascular endothelial growth fa ...... on and therapeutic potentials.
@ast
Vascular endothelial growth fa ...... on and therapeutic potentials.
@en
P2860
P1476
Vascular endothelial growth fa ...... ion and therapeutic potentials
@en
P2093
Nader Rahimi
P2860
P304
P356
10.1016/J.EXER.2006.03.019
P50
P577
2006-05-19T00:00:00Z